Please use this identifier to cite or link to this item:
Title: What factors determine patients' preference for tumour necrosis factor inhibitors in ankylosing spondylitis?
Austin Authors: Fajri, Dessy W;Brand, Caroline A;Dharmage, Shyamali C;Martin, Belinda J;Buchanan, Russell R C ;Schachna, Lionel 
Affiliation: Department of Rheumatology, Austin Health, Heidelberg, Victoria, Australia
Issue Date: 14-Feb-2009
Publication information: Clinical Rheumatology 2009; 28(5): 599-602
Abstract: Tumour necrosis factor inhibitor (TNFi) therapy, either intravenous (IV) or subcutaneous (SQ), demonstrates similar efficacy in ankylosing spondylitis (AS). The objective of this study was to examine factors influencing patient preference of TNFi. Fifty-nine (79.7%) participants were male with mean age 43.9 years and disease duration of 22.0 years. Fifty-nine patients (79.7%) agreed with the statement 'My doctor gave me a choice and I made a decision based on my personal preference'. Patients commenced first on IV TNFi most commonly cited reduced frequency of injections (96.6%), administration by a trained professional (89.7%) and use of infusion time for leisure activities (86.2%). Patients commenced on SQ TNFi cited flexibility with timing of treatment (80%), shortened administration time (73.3%) and the convenience of home therapy (73.3%). Shared clinical decision-making between clinicians and patients may be desirable for AS patients commencing TNFi therapy.
Gov't Doc #: 19219481
DOI: 10.1007/s10067-009-1104-4
Journal: Clinical rheumatology
Type: Journal Article
Subjects: Adult
Antirheumatic Agents.therapeutic use
Infusions, Intravenous
Injections, Subcutaneous
Middle Aged
Patient Satisfaction
Spondylitis, Ankylosing.drug therapy
Treatment Outcome
Tumor Necrosis Factor-alpha.antagonists & inhibitors
Appears in Collections:Journal articles

Files in This Item:
File SizeFormat 
19219481.pdf47.98 kBAdobe PDFView/Open
Show full item record

Page view(s)

checked on Dec 7, 2023


checked on Dec 7, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.